Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -667.45% is 26% above its 1-year average of -902.31%, near the high end of its 1-year range (-1825.34%–-214.14%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly EBITDA margin; no daily interpolation. Q3 FY2026 (2026-06-30): -667.45%.
EBITDA MARGIN
-667.45%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Citius Pharmaceuticals, Inc.
Market Cap
$13.20M
EBITDA Margin
-667.45%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.53M
EBITDA Margin
-839.37%
TTM Avg
-1027.77%
3Y Avg
-3215.79%
5Y Avg
-3215.79%
Market Cap
$12.77M
EBITDA Margin
-34.02%
TTM Avg
-37.67%
3Y Avg
-64.98%
5Y Avg
-56.41%
Market Cap
$12.51M
EBITDA Margin
-1106.68%
TTM Avg
-120183.14%
3Y Avg
-60445.11%
5Y Avg
-60445.11%
Market Cap
$13.99M
EBITDA Margin
-988.11%
TTM Avg
-1002.20%
3Y Avg
-1043.90%
5Y Avg
-1194.77%
Market Cap
$12.54M
EBITDA Margin
-16245.70%
TTM Avg
-13416.38%
3Y Avg
-13330.05%
5Y Avg
-20098.17%
Market Cap
$12.51M
EBITDA Margin
-6933.56%
TTM Avg
-9498.48%
3Y Avg
-11253.22%
5Y Avg
-11253.22%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | $13.20M | -667.45% | N/A | N/A | N/A |
| IN8bio, Inc. (INAB)vs › | $13.33M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $13.08M | N/A | N/A | N/A | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.53M | -839.37% | -1027.77% | -3215.79% | -3215.79% |
| Cytosorbents Corporation (CTSO)vs › | $12.77M | -34.02% | -37.67% | -64.98% | -56.41% |
| Dare Bioscience, Inc. (DARE)vs › | $12.51M | -1106.68% | -120183.14% | -60445.11% | -60445.11% |
| Sintx Technologies, Inc. (SINT)vs › | $13.99M | -988.11% | -1002.20% | -1043.90% | -1194.77% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.54M | -16245.70% | -13416.38% | -13330.05% | -20098.17% |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.51M | -6933.56% | -9498.48% | -11253.22% | -11253.22% |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.03M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
-667.4%
Operating Margin
0.0%
Net Margin
-651.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -667.45% |
| 2026-03-31 | -1825.34% |
| 2025-12-31 | -214.14% |
